Refocus Proves Profitable in Nutraceutix 1QRefocus Proves Profitable in Nutraceutix 1Q
June 1, 2000
Refocus Proves Profitable in Nutraceutix 1Q
REDMOND,Wash.--Nutraceutix Inc. (OTC BB:NUTX) reported significant sales and profit gains for itsfirst quarter ended March 31, owing largely to a shift in focus from non-proprietaryproducts to proprietary technologies. Net sales peaked at $2.1 million, up 30 percent from$1.6 million sold in the same period last year. Gross profit also improved, up more thanone point as a percentage of sales. Turning in an even bigger improvement were totaloperating costs, which fell almost 11 points as a percentage of sales. Big improvementswere especially noted in selling and marketing expenses. On the strength of the operatingresults, net loss was cut to $.04 million or $.002 per share from $.32 million or $.019per share lost in the comparable 1999 quarter.
Management reported that sales from proprietary technology rocketed 276 percent to $1.3million from $.36 million sold in the equivalent period last year. Conversely, revenuesfrom private label manufacturing of health supplements plummeted 76 percent in comparingthe same two periods. NUTX noted that a large portion of such sales in the comparable 1999quarter were credited to an interim service provided to Met-Rx, which was not then readyto introduce its own powder fill product to the bodybuilding market. NUTX stated that itdoes not expect to continue its powder fill business in 2000.
You May Also Like
The rise of ashwagandha: A case study in a growing and evolving category – articleNov 28, 2023
Ashwagandha: Roots for wellness, leaves for soil – articleNov 28, 2023
Creatine, whey protein, beta-alanine among picks in NFL-style draft at SupplySide WestDec 01, 2023
Unleash the power of ‘combos’ supplements to meet consumer demand – infographicNov 22, 2023